Harvard Bioscience (NASDAQ:HBIO - Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of $0.06 per share for the quarter. Individual that wish to listen to the company's earnings conference call can do so using this link.
Harvard Bioscience (NASDAQ:HBIO - Get Free Report) last posted its quarterly earnings data on Thursday, March 7th. The medical instruments supplier reported $0.01 earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.02). The firm had revenue of $28.15 million during the quarter, compared to analysts' expectations of $27.80 million. Harvard Bioscience had a negative net margin of 3.04% and a positive return on equity of 2.75%.
Harvard Bioscience Stock Performance
HBIO traded up $0.11 during trading on Tuesday, hitting $3.82. The stock had a trading volume of 206,610 shares, compared to its average volume of 87,701. Harvard Bioscience has a twelve month low of $3.44 and a twelve month high of $6.29. The firm has a market capitalization of $165.79 million, a P/E ratio of -46.37 and a beta of 1.42. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.92 and a current ratio of 1.85. The company's 50-day moving average price is $4.21 and its 200 day moving average price is $4.47.
Harvard Bioscience Company Profile
(
Get Free Report)
Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.
See Also
Before you consider Harvard Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harvard Bioscience wasn't on the list.
While Harvard Bioscience currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
